Overview
Clinical Trials Participation:
Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Activity Of Ibudilast (Mn-166) In Subjects With Progressive Multiple Sclerosis
Principal Investigator/National Study Lead
A multicenter, observational, open-label, single arm, study of Tysabri in early Relapsing-remitting Multiple Scelrosis in anti-JVC antibody negative patients. (STRIVE)
Principal Investigator
A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis.
Highlights
- 1
- 2
- 3
Publications
33 publications
Funding
1 grant
Completed grants (1)
- Sub-PIU01NS082329-01NeuroNEXTNational Institute of Neurological Disorders and Stroke · 2013–2018 · via Harvard Medical School
Clinical research
3 studies
Active
1 study- PIStudy of Southeast Asians with MS in Comparison to Black and White Americans with MSWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (2)
- PINCT04281160Patient Centered Outcomes Analysis for MS Using a Mobile ApplicationWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)Multiple Sclerosis
- PIA randomized study comparing the effectiveness and impact of Telemedicine in addition to standard care versus standard care alone to manage tolerability, adherence and related patient reported outcomes in patients with relapsing forms of multiple sclerosis newly treated with diroximel fumarate (Vumerity)Biogen, Inc. · IRB STUDY CLOSURE (as of 2023)
External relationships
Other Interest
EMD Serono, Inc. · TG Therapeutics, Inc.
Other
EMD Serono, Inc.